List of Figures
Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018 34
Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016–2023 38
Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016–2023 39
Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016–2023 40
Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016–2023 41
Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016–2023 42
Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 50
Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006–2024 52
Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014–2024 55
Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014–2024 57
Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016–2024 59
Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015–2024 60
Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017–2024 62
Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006–2024 64
Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013–2024 66
Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018–2024 68
Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013–2024 69
Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011–2024 71
Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2024 73
Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017–2024 75
Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 76
Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018 77
Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 78
Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 79
Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018 81
Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 82
Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006–2018 83
Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2018 84
Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2018 85
Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2018 86
Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018 87
Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018 88
Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018 89
Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2018 90
Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018 91
Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2018 92
Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2018 93
Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2018 94
Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018 95
Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2018 96
Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2018 97
Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2018 98
Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018–2024 100
Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018–2024 101
Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018–2024 103
Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019–2024 104
Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020–2024 105
Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020–2024 107
Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017–2024 108
Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017–2024 112
Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024 113
Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017–2024 114
Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017–2024 116
Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017–2024 117
Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017–2024 118
Figure 56: Cancer Immunotherapies Drugs Market, Global, Company Analysis Matrix, 2017–2024 119
Figure 57: Cancer Immunotherapies Drugs Market, Global, Cluster by Growth and Market Share, 2017–2024 120
Figure 58: Cancer Immunotherapies Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024 122
Figure 59: Cancer Immunotherapies Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024 123
Figure 60: Cancer Immunotherapies Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024 124
Figure 61: Cancer Immunotherapies Drugs Market, Global, Celgene Annual Revenue Forecast ($bn), 2017–2024 125
Figure 62: Cancer Immunotherapies Drugs Market, Global, Merck & Co Annual Revenue Forecast ($bn), 2017–2024 126
Figure 63: Cancer Immunotherapies Drugs Market, Global, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2017–2024 127
Figure 64: Cancer Immunotherapies Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2017–2024 128
Figure 65: Cancer Immunotherapies Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2017–2024 129
Figure 66: Cancer Immunotherapies Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024 130
Figure 67: Cancer Immunotherapies Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2024 131
Figure 68: Cancer Immunotherapies Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2018–2024 132
Figure 69: Cancer Immunotherapies Drugs Market, Global, Gilead Sciences Annual Revenue Forecast ($bn), 2018–2024 133
Figure 70: Cancer Immunotherapies Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017–2024 134
Figure 71: Cancer Immunotherapies Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2018 135
Figure 72: Cancer Immunotherapies Drugs Market, Global, Overall High-Activity and Late-Stage Pipeline Developers by Level of Cancer Immunotherapies Specialization, 2018 136
Figure 73: Cancer Immunotherapies Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2017–2024 137
Figure 74: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Region, Deal Value and Year, 2006–2018 139
Figure 75: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Indication, 2006–2018 140
Figure 76: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018 141
Figure 77: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018 142
Figure 78: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018 155
Figure 79: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Indication, 2006–2018 156
Figure 80: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018 157
Figure 81: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018 158
Figure 82: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 1 178
Figure 83: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 2 179
Figure 84: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 3 180
Figure 85: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 4 181
Figure 86: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 5 182
Figure 87: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 6 183
Figure 88: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 7 184
Figure 89: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 8 185
Figure 90: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 9 186
Figure 91: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 10 187
Figure 92: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 11 188
Figure 93: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 12 189
Figure 94: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 13 190
Figure 95: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 14 191
Figure 96: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 15 192
Figure 97: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 16 193
Figure 98: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 17 194
Figure 99: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 18 195
Figure 100: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 19 196
Figure 101: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 20 197
Figure 102: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 21 198
Figure 103: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 22 199
Figure 104: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 23 200
Figure 105: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 24 201
Figure 106: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 25 202
Figure 107: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 26 203